Clinical trials: Cancer - Ovarian
Ovarian Cancer
Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected
The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory…
- Trial name
- NCT04729387
- Testing
- Alpelisib, Olaparib, Paclitaxel
- Where
- 93 sites in United States, Argentina and 24 more
- Volunteers
- 358 people
- Sponsor
- Novartis Pharmaceuticals
Brenner Tumor, Fallopian Tube Cancer
Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or Cisplatin
This phase II trial is studying how well giving belinostat together with carboplatin works in treating patients with recurrent or persistent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer that did…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT00993616
- Testing
- belinostat, carboplatin
- Where
- 81 sites in United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Cancer, Bladder Cancer
Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)
This is a proof-of-concept pilot randomized clinical trial to test the feasibility of the innovative Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) to enhance personalized supportive care for cancer…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- PRISMS (NCT04492007)
- Testing
- Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Ovarian Cancer
A Study Of Avelumab Alone Or In Combination With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer (JAVELIN Ovarian 200)
A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with…
- Trial name
- NCT02580058
- Testing
- avelumab, PLD
- Where
- 295 sites in United States, Australia and 23 more
- Volunteers
- 566 people
- Sponsor
- Pfizer
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Brenner Tumor, Fallopian Tube Cancer
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
This phase II trial is studying the side effects of giving erlotinib together with carboplatin and paclitaxel and to see how well it works in treating patients with stage III or stage IV ovarian, fallopian tube, or primary…
- Conditions
- Brenner Tumor, Fallopian Tube Cancer, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma
- Trial name
- NCT00059787
- Testing
- paclitaxel, carboplatin, erlotinib
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm
Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1
This phase I/IIa trial studies the side effects and best dose of gene-modified T cells when given with or without decitabine, and to see how well they work in treating patients with malignancies expressing cancer-testis antigens…
- Conditions
- Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma, Advanced Ovarian Carcinoma
- Trial name
- NCT02650986
- Testing
- Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Roswell Park Cancer Institute
Ovarian Cancer, Neoplasms, Ovarian
Second-Line Therapy Study For Potentially Platinum-Sensitive Relapsed Ovarian Cancer
This study was designed to find the most effective and safest doses of both HYCAMTIN and CARBOPLATIN that can be given for the treatment of ovarian cancer.
- Trial name
- NCT00316173
- Testing
- topotecan, CARBOPLATIN
- Where
- 22 sites in United States, Canada
- Volunteers
- 77 people
- Sponsor
- GlaxoSmithKline
Cancer
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
RATIONALE: Antithymocyte globulin, clofarabine, and rituximab may stop the patient's immune system from rejecting the donor's stem cells when they do not exactly match the patient's blood.
- Trial name
- NCT00617929
- Testing
- anti-thymocyte globulin, rituximab, clofarabine
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Ovarian Cancer, Fallopian Tube Cancer
MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase I study to establish safety and feasibility of intraperitoneally administered lentiviral transduced MOv19-BBz CAR T cells with or without cyclophosphamide + fludarabine as lymphodepleting chemotherapy
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
- Trial name
- NCT03585764
- Testing
- MOv19-BBz CAR T cells, Alpha Folate Receptor expression test
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- University of Pennsylvania
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
This randomized phase II trial studies how well nivolumab works with or without ipilimumab in treating patients with epithelial ovarian, primary peritoneal, or fallopian tube cancer that has not responded after prior treatment…
- Conditions
- Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
- Trial name
- NCT02498600
- Testing
- Ipilimumab, Nivolumab
- Where
- 201 sites in United States
- Volunteers
- 100 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms
Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell Cancers
Background: Chemotherapy damages cancer cell deoxyribonucleic acid (DNA) so the cells die, and the tumor shrinks. But it may stop working in some people over time.
- Conditions
- Carcinoma, Non-Small -Cell Lung, Ovarian Neoplasms, Small Cell Lung Carcinoma, Uterine Cervical Neoplasms
- Trial name
- NCT02487095
- Testing
- Topotecan, VX-970 (M6620)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Neoplasms, Fallopian Tube Neoplasms
Phase II Study of Clinical Activity of Pegaspargase in Women With Relapsed or Refractory Epithelial Ovarian Cancer, Fallopian Tube Cancer, and/or Primary Peritoneal Cancer
Background: The best treatment for ovarian and related female reproductive tract cancers is not yet known for patients whose disease has not responded to or has recurred after standard treatment.
- Conditions
- Ovarian Neoplasms, Fallopian Tube Neoplasms, Primary Peritoneal Neoplasms
- Trial name
- NCT01313078
- Testing
- Pegylated L-Asparaginase
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Non-small Cell Lung Cancer
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1/2, dose-escalation study with expansion cohorts to evaluate NM21-1480 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2…
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Colorectal Cancer, Squamous Cell Carcinoma
- Trial name
- NCT04442126
- Testing
- NM21-1480
- Where
- 26 sites in United States, Spain and 1 more
- Volunteers
- 52 people
- Sponsor
- Numab Therapeutics AG
Ovarian Cancer, Fallopian Tube Cancer
A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)
This trial will study tisotumab vedotin to find out what its side effects are and to see if it works for platinum-resistant ovarian cancer (PROC).
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Trial name
- NCT03657043
- Testing
- tisotumab vedotin
- Where
- 37 sites in United States, Belgium and 4 more
- Volunteers
- 98 people
- Sponsor
- Seagen Inc.
Epithelial Ovarian Cancer, Peritoneal Neoplasms
Birinapant for Advanced Ovarian, Fallopian Tube, and Peritoneal Cancer
Background: Birinapant is an experimental cancer treatment drug. It removes certain proteins in cells, which helps to kill the cells.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Neoplasms
- Trial name
- NCT01681368
- Testing
- Birinapant (TL32711)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- National Cancer Institute (NCI)
Fallopian Tube Cancer, Ovarian Cancer
Docetaxel and Capecitabine in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cavity Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00354601
- Testing
- capecitabine, docetaxel
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Ovarian Cancer
Study of Bevacizumab/Doxil in Treatment of Platinum-Resistant/Refractory Ovarian Cancer (CA)
The purpose of this research study is to test the safety, tolerability, and effectiveness of two chemotherapy drugs, pegylated liposomal doxorubicin (Doxil) and bevacizumab (Avastin).
- Trial name
- NCT00945139
- Testing
- Doxil, Avastin
- Where
- 3 sites in United States
- Volunteers
- 46 people
- Sponsor
- New Mexico Cancer Research Alliance
Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
This phase II/III trial studies how well pegylated liposomal doxorubicin hydrochloride with atezolizumab and/or bevacizumab work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back…
- Conditions
- Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
- Trial name
- NCT02839707
- Testing
- Atezolizumab, Bevacizumab, Computed Tomography
- Where
- 919 sites in United States, Puerto Rico
- Volunteers
- 444 people
- Sponsor
- National Cancer Institute (NCI)